Iambic, a clinical-stage life science and technology company headquartered in San Diego, announced that it has raised more than $100 million in an oversubscribed financing round. The round drew participation from a broad group of new and existing investors spanning life sciences, growth equity, technology, and sovereign wealth funds. Participating investors included Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.
The financing follows a period of notable progress across Iambic’s pipeline and platform. The company recently shared clinical data for IAM1363 at the European Society for Medical Oncology Congress. The data demonstrated anti-tumor activity and a favorable safety profile across both HER2-wild-type and HER2-mutated cancers in multiple patient groups. Following that announcement, Iambic entered into a research collaboration with Jazz Pharmaceuticals to evaluate the combination of zanidatamab with IAM1363 in patients with HER2-positive breast cancer previously treated with Enhertu.
Additionally, Iambic announced a collaboration earlier this year with Revolution Medicines that provides access to proprietary data from Revolution Medicines and access to Iambic’s NeuralPLexer protein-ligand structure prediction technology. The company also advanced its Enchant multimodal transformer model, which achieved strong performance across clinical and preclinical predictive benchmarks.
Founded in 2020, Iambic has developed an AI-driven discovery and development platform integrating multimodal predictive modeling, physics-based molecular design, and automated laboratory execution. The platform is designed to accelerate discovery cycles and expand the druggable target space. The company expects its KIF18A and CDK2/4 programs to advance into clinical development and anticipates additional partnerships and technology collaborations.
KEY QUOTES:
“We are thrilled to have the support of many outstanding and committed investors who are partnering with Iambic to advance our mission of creating technologies to bring better medicines to patients.”
Tom Miller, PhD, Co-Founder and CEO, Iambic
“We are proud of the scientific and business progress Iambic has made across its pipeline, partnerships, and platform over this past year and view this fundraise as a testament to the exceptional work of the Iambic team. We look forward to continuing Iambic’s progress and anticipate our KIF18A and CDK2/4 programs entering the clinic as well as additional discovery and technology enablement collaborations in the near term.”
Tom Miller, PhD, Co-Founder and CEO, Iambic
